Virpax Pharmaceuticals In... (VRPX)
Company Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.
Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Country | United States |
IPO Date | Feb 17, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2 |
CEO | Jatinder Dhaliwal |
Contact Details
Address: 1055 Westlakes Drive Berwyn, Pennsylvania United States | |
Website | https://www.virpaxpharma.com |
Stock Details
Ticker Symbol | VRPX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001708331 |
CUSIP Number | 928251206 |
ISIN Number | US9282512063 |
Employer ID | 82-1510982 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jatinder Dhaliwal | Chief Executive Officer & Chairman |
Usama Chaudhry | Chief Financial Officer & Corporate Secretary |
Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 03, 2025 | 8-K/A | [Amend] Current Report |
Apr 03, 2025 | 8-K | Current Report |
Mar 25, 2025 | S-1/A | [Amend] Filing |
Mar 21, 2025 | 8-K | Current Report |
Mar 17, 2025 | S-1 | Filing |
Mar 03, 2025 | 10-K | Annual Report |
Feb 06, 2025 | 8-K | Current Report |
Feb 04, 2025 | 8-K | Current Report |
Jan 30, 2025 | 8-K | Current Report |
Jan 28, 2025 | 424B4 | Filing |